Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 128 citing articles:

Gene therapy returns to centre stage
Luigi Naldini
Nature (2015) Vol. 526, Iss. 7573, pp. 351-360
Closed Access | Times Cited: 1049
A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA
Katie Ewer, Tommy Rampling, Navin Venkatraman, et al.
New England Journal of Medicine (2015) Vol. 374, Iss. 17, pp. 1635-1646
Open Access | Times Cited: 346
Malaria Vaccines: Recent Advances and New Horizons
Simon J. Draper, Brandon K. Sack, C. Richter King, et al.
Cell Host & Microbe (2018) Vol. 24, Iss. 1, pp. 43-56
Open Access | Times Cited: 299
Safety and efficacy of PfSPZ Vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial
Mahamadou S. Sissoko, Sara A. Healy, Abdoulaye Katilé, et al.
The Lancet Infectious Diseases (2017) Vol. 17, Iss. 5, pp. 498-509
Open Access | Times Cited: 296
Chimpanzee Adenovirus Vector Ebola Vaccine — Preliminary Report
Julie E. Ledgerwood, Nancy J. Sullivan, Barney S. Graham
New England Journal of Medicine (2015) Vol. 373, Iss. 8, pp. 775-776
Closed Access | Times Cited: 246
Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine
Katharine A. Collins, Rebecca Snaith, Matthew G. Cottingham, et al.
Scientific Reports (2017) Vol. 7, Iss. 1
Open Access | Times Cited: 210
Challenges and strategies for developing efficacious and long-lasting malaria vaccines
James G. Beeson, Liriye Kurtovic, Carlota Dobaño, et al.
Science Translational Medicine (2019) Vol. 11, Iss. 474
Open Access | Times Cited: 181
Viral vectors as vaccine platforms: from immunogenicity to impact
Katie Ewer, Teresa Lambe, Christine S. Rollier, et al.
Current Opinion in Immunology (2016) Vol. 41, pp. 47-54
Open Access | Times Cited: 176
Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results
Christine D. Palmer, Amy Rappaport, Matthew J. Davis, et al.
Nature Medicine (2022) Vol. 28, Iss. 8, pp. 1619-1629
Open Access | Times Cited: 134
A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results
Amy Rappaport, Chrisann Kyi, Monica Lane, et al.
Nature Medicine (2024) Vol. 30, Iss. 4, pp. 1013-1022
Closed Access | Times Cited: 32
Malaria prevention: from immunological concepts to effective vaccines and protective antibodies
Ian A. Cockburn, Robert A. Seder
Nature Immunology (2018) Vol. 19, Iss. 11, pp. 1199-1211
Open Access | Times Cited: 154
Oral vaccination of fish: Lessons from humans and veterinary species
Carmen W. E. Embregts, Maria Forlenza
Developmental & Comparative Immunology (2016) Vol. 64, pp. 118-137
Open Access | Times Cited: 153
Update on Tumor Neoantigens and Their Utility: Why It Is Good to Be Different
Chung‐Han Lee, Roman Yelensky, Karin Jooss, et al.
Trends in Immunology (2018) Vol. 39, Iss. 7, pp. 536-548
Open Access | Times Cited: 152
Factors Which Contribute to the Immunogenicity of Non-replicating Adenoviral Vectored Vaccines
Lynda Coughlan
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 118
Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01BWith Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAP
Tommy Rampling, Katie Ewer, Georgina Bowyer, et al.
The Journal of Infectious Diseases (2016) Vol. 214, Iss. 5, pp. 772-781
Open Access | Times Cited: 89
New viral vectors for infectious diseases and cancer
Emanuele Sasso, Anna Morena D’Alise, Nicola Zambrano, et al.
Seminars in Immunology (2020) Vol. 50, pp. 101430-101430
Open Access | Times Cited: 86
Malaria Vaccines: Progress to Date
Danielle I. Stanisic, Michael F. Good
BioDrugs (2023) Vol. 37, Iss. 6, pp. 737-756
Open Access | Times Cited: 34
Superior antibody immunogenicity of a viral-vectored RH5 blood-stage malaria vaccine in Tanzanian infants as compared to adults
Sarah E. Silk, Wilmina F. Kalinga, Ivanny M. Mtaka, et al.
Med (2023) Vol. 4, Iss. 10, pp. 668-686.e7
Open Access | Times Cited: 27
Recombinant Chimpanzee Adenovirus Vaccine AdC7-M/E Protects against Zika Virus Infection and Testis Damage
Kun Xu, Yufeng Song, Lianpan Dai, et al.
Journal of Virology (2018) Vol. 92, Iss. 6
Open Access | Times Cited: 78
Chimpanzee adenoviral vectors as vaccines for outbreak pathogens
Katie Ewer, Sarah Sebastian, Alexandra J. Spencer, et al.
Human Vaccines & Immunotherapeutics (2017) Vol. 13, Iss. 12, pp. 3020-3032
Open Access | Times Cited: 77
A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime – MVA85A boost in healthy UK adults
Morven Wilkie, Iman Satti, Alice Minhinnick, et al.
Vaccine (2019) Vol. 38, Iss. 4, pp. 779-789
Open Access | Times Cited: 73
Prime and target immunization protects against liver-stage malaria in mice
Anita Gola, Daniel Silman, Adam A. Walters, et al.
Science Translational Medicine (2018) Vol. 10, Iss. 460
Open Access | Times Cited: 69
Controlled Human Malaria Infection of Healthy Adults With Lifelong Malaria Exposure to Assess Safety, Immunogenicity, and Efficacy of the Asexual Blood Stage Malaria Vaccine Candidate GMZ2
Jean Claude Dejon‐Agobé, Ulysse Ateba-Ngoa, Albert Lalremruata, et al.
Clinical Infectious Diseases (2018) Vol. 69, Iss. 8, pp. 1377-1384
Open Access | Times Cited: 69
The Promise of a Malaria Vaccine—Are We Closer?
Matthew B. Laurens
Annual Review of Microbiology (2018) Vol. 72, Iss. 1, pp. 273-292
Open Access | Times Cited: 60
First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children
Alfred B. Tiono, Issa Nèbiè, Nicholas Anagnostou, et al.
PLoS ONE (2018) Vol. 13, Iss. 12, pp. e0208328-e0208328
Open Access | Times Cited: 59
Page 1 - Next Page

Scroll to top